List of Excipients in Branded Drug PARAPLATIN

Generic Drugs Containing PARAPLATIN

Company	Ingredient	NDC	Excipient
Accord BioPharma Inc	carboplatin	69448-005	WATER

What are the Most Frequently-Used Excipients in PARAPLATIN?

# Of NDCs	Excipient
1	WATER

Paraplatin Excipient Strategy and Commercial Opportunities for Carboplatin

Last updated: September 5, 2026

Paraplatin is the original branded formulation of carboplatin, a platinum-based antineoplastic supplied as a sterile aqueous injection. Its commercial and patent value is no longer concentrated in the active ingredient. Carboplatin's core composition-of-matter protection has expired, and generic injectable products dominate the market. The strongest remaining opportunities are excipient-enabled improvements in stability, packaging, ready-to-administer delivery, preparation safety, and supply reliability.

What is Paraplatin and which excipients does it contain?

Paraplatin is an injectable formulation of carboplatin, generally supplied at a concentration of 10 mg/mL in sterile aqueous solution. The formulation is intentionally simple. The principal excipient is Water for Injection, with no therapeutic co-active ingredient required for solubility or delivery in the conventional product configuration (U.S. Food and Drug Administration [FDA], 2023).

Attribute	Paraplatin and conventional carboplatin injection
Active ingredient	Carboplatin
Drug class	Platinum coordination complex
Dosage form	Sterile intravenous injection
Conventional concentration	10 mg/mL
Primary excipient	Water for Injection
Preservative strategy	Preservative-free single-use presentation
Administration	Intravenous infusion after dilution
Key compatibility issue	Avoidance of aluminum-containing needles and administration components
Core patent position	Expired
Biosimilar pathway	Not applicable
Primary competing products	Generic carboplatin injections

The absence of buffers, surfactants, antioxidants, and preservatives reduces excipient-related toxicity and simplifies regulatory comparability. It also limits opportunities to differentiate a conventional vial through a new composition alone.

Carboplatin is administered intravenously and is typically diluted before infusion in compatible solutions such as 5% dextrose or 0.9% sodium chloride, subject to the applicable product label and institutional handling procedures (FDA, 2023). The formulation is cytotoxic and requires preparation within oncology pharmacy controls.

What excipient strategy protects carboplatin stability?

The core excipient strategy is minimalism. Carboplatin does not require a complex solubilization system, and adding formulation components can create new toxicology, compatibility, extractables, and manufacturing burdens.

Aqueous stability

The commercial value of a carboplatin formulation depends on maintaining assay, impurity limits, sterility, and particulate control over the labeled shelf life. A stable aqueous solution is preferable to a reconstituted lyophilized product when the manufacturer can control container closure, sterilization, and distribution conditions.

Potential formulation variables include:

• pH control;
• ionic strength;
• concentration;
• container-closure composition;
• oxygen exposure;
• light exposure;
• storage temperature;
• dilution stability;
• adsorption to administration components; and
• trace-metal contamination.

A formulation developer must avoid changing carboplatin's coordination chemistry without a clear clinical or manufacturing benefit. The addition of chloride-containing materials can be particularly relevant because platinum complexes may undergo ligand exchange reactions. Carboplatin is generally more kinetically stable than cisplatin, but compatibility remains a product-specific issue and must be validated experimentally.

Aluminum avoidance

Carboplatin products carry a significant materials-compatibility constraint. Contact with aluminum can cause visible discoloration or precipitation and reduce delivered drug potency. Labels therefore instruct users to avoid aluminum-containing needles, syringes, or administration components (FDA, 2023).

This constraint creates an excipient-adjacent commercial opportunity. The value is not necessarily a new chemical excipient. It is a validated delivery system that combines:

• aluminum-free primary packaging;
• aluminum-free transfer devices;
• compatible elastomers;
• low-sorption tubing;
• closed-system transfer technology;
• validated storage and dilution instructions; and
• clear pharmacy workflow controls.

A supplier that can document reliable compatibility across vial, syringe, transfer device, and infusion set may have a stronger commercial position than a supplier offering another conventional vial.

What formulations are protected or commercially differentiated?

The conventional carboplatin composition is difficult to protect broadly because the active ingredient is off-patent and the aqueous formulation is technically straightforward. Patentable differentiation is more likely in a defined combination of formulation and use conditions.

Potential formulation claims

A new carboplatin product could pursue claims covering:

1. A defined concentration range with extended room-temperature stability.
2. A formulation with specified impurity limits after dilution.
3. A low-particulate, low-sorption container-closure system.
4. A ready-to-use infusion bag with validated in-use stability.
5. A formulation that eliminates pharmacy reconstitution or dilution steps.
6. A terminally sterilized presentation with a defined shelf life.
7. A container and administration set that prevents aluminum contact.
8. A formulation optimized for automated compounding systems.
9. A prefilled syringe or cartridge for controlled oncology dispensing.
10. A dual-compartment system separating drug and diluent until administration.

The strongest claims would generally combine composition, packaging, and performance data. A claim covering only "carboplatin in water" would face substantial novelty and obviousness risk in view of the established product and generic market.

Lyophilized versus liquid presentations

A lyophilized product could improve shipping flexibility or permit a different stability profile, but it introduces reconstitution steps, particulate risk, operator exposure, and additional manufacturing cost. A liquid product has a simpler pharmacy workflow and is better positioned for ready-to-use distribution.

Formulation type	Commercial advantage	Main drawback	Opportunity level
Conventional aqueous vial	Low manufacturing complexity	Limited differentiation	Low
Higher-concentration aqueous vial	Lower shipping and handling volume	Stability and administration validation	Moderate
Ready-to-use infusion bag	Reduces pharmacy preparation	Shorter dating and bag compatibility	High
Prefilled syringe	Workflow efficiency	Dose flexibility and cytotoxic handling	Moderate
Lyophilized vial	Potential stability and logistics benefits	Reconstitution and operator burden	Moderate
Dual-chamber system	Separates drug and diluent	Device complexity and cost	Moderate to high
Closed-system oncology presentation	Reduces exposure and preparation steps	Requires device validation	High

When did Paraplatin lose exclusivity?

Paraplatin's core patent protection expired years ago. The relevant U.S. patent is generally identified as U.S. Patent No. 4,657,927, covering carboplatin-related subject matter. The patent was issued in 1987 and had an original term that placed expiration in the early 2000s, subject to the patent-term rules applicable at the time (U.S. Patent and Trademark Office [USPTO], 1987).

The FDA approved carboplatin for ovarian cancer in 1989. Generic carboplatin injections subsequently entered through the abbreviated new drug application pathway. The original active-ingredient patent is therefore not a current barrier to generic entry.

Milestone	Approximate timing
Carboplatin patent issued	1987
FDA approval of Paraplatin	1989
Core patent expiration period	Early 2000s
Generic injectable competition	Established
Current branded exclusivity	None identified in the conventional product
Current Orange Book patent barrier	No material barrier identified

What is the Orange Book status of Paraplatin?

The Orange Book is relevant to listed drug patents, regulatory exclusivity, therapeutic equivalence, and generic approval status. Paraplatin's commercial protection is not comparable to that of a recently approved small-molecule product with unexpired composition, formulation, or method-of-use patents.

The commercial consequences are:

• No meaningful current market exclusivity based on the original carboplatin patent.
• No biosimilar framework because carboplatin is a small molecule, not a biologic.
• Generic competition through ANDAs.
• Limited ability to block approval through a conventional Paragraph IV strategy directed at expired core patents.
• Any new patent value would need to arise from a later formulation, device, manufacturing process, or narrowly defined method of use.

A later entrant could still face regulatory or litigation issues if a competitor lists valid patents covering a specific new presentation. Those rights would not restore broad exclusivity to conventional carboplatin injection.

Which companies are challenging Paraplatin exclusivity?

The relevant competitive challenge has already occurred through generic entry rather than through a current branded-versus-generic patent dispute. Multiple manufacturers have supplied carboplatin injection in the United States and other markets, subject to national approvals and product availability.

Because carboplatin is an established injectable, competition is shaped by:

• approved manufacturing capacity;
• sterile-fill reliability;
• oncology product shortages;
• hospital contracting;
• purchase-group pricing;
• vial sizes;
• ready-to-use availability;
• quality history; and
• supply continuity.

A Paragraph IV challenge to an expired carboplatin core patent would have little commercial effect. The more relevant patent disputes would concern a differentiated formulation, delivery device, stability method, or manufacturing process.

What manufacturing and intellectual-property barriers remain?

The principal barriers are operational rather than molecule-based.

Sterile manufacturing

Carboplatin injection requires validated sterile manufacturing, aseptic processing or an appropriate sterilization strategy, container-closure integrity testing, particulate control, and cytotoxic containment. These requirements create meaningful capital and quality-system barriers even when patent protection is absent.

Packaging compatibility

The manufacturer must validate:

• vial glass and coating;
• stopper formulation;
• aluminum seal configuration;
• syringe and tubing compatibility;
• extractables and leachables;
• adsorption and recovery;
• visible and subvisible particles;
• shipping vibration and temperature excursions; and
• compatibility with automated compounding equipment.

Manufacturing-process patents

Potential process claims could cover impurity reduction, crystallization, high-purity carboplatin starting material, sterile filtration, container filling, or extended stability. Such rights would generally be narrower than a composition patent and would require evidence that the accused product practices the claimed process.

A process patent is commercially stronger when the process is difficult to design around or when the resulting quality attribute is necessary for regulatory approval. It is weaker when an alternative manufacturing route can produce the same active ingredient at comparable cost.

What commercial opportunities exist for carboplatin excipients and delivery systems?

The largest opportunity is not a new excipient. It is a product that reduces total treatment cost and pharmacy labor.

Ready-to-use oncology products

A ready-to-use carboplatin infusion bag could reduce:

• pharmacy compounding time;
• drug waste;
• occupational exposure;
• dose-calculation errors;
• preparation variability; and
• dependence on compounding capacity during shortages.

The business case depends on shelf life, dose customization, reimbursement, and hospital purchasing. A short-dated bag may not compete effectively with a low-cost vial unless it offers reliable supply or measurable labor savings.

High-concentration products

A higher-concentration solution could reduce freight volume and storage requirements. The commercial value would depend on whether the concentration is compatible with infusion protocols and whether it creates local tolerability, dosing, or administration constraints.

Closed-system transfer components

Carboplatin is used in oncology settings where hazardous-drug handling is regulated. A package that integrates the vial with a compatible closed-system transfer device could command a premium if it reduces preparation steps and aligns with institutional hazardous-drug policies.

Co-packaged diluent systems

A carboplatin vial co-packaged with a validated diluent or transfer system could simplify procurement. The product would need to preserve flexibility across patient-specific dosing while avoiding unnecessary packaging cost.

Global-market formulations

Outside the United States, opportunity may exist in markets where injectable oncology supply is fragmented or where hospital pharmacies have limited compounding infrastructure. Geographic value will depend on:

• national registration;
• local GMP compliance;
• public tender systems;
• cold-chain requirements;
• local shortage conditions;
• approved vial sizes; and
• reimbursement controls.

Patent rights must be assessed separately by jurisdiction. U.S. expiration does not establish freedom to operate in Europe, Japan, China, India, or other markets, although the underlying core patent is also old in most jurisdictions.

How does Paraplatin compare with cisplatin?

Carboplatin and cisplatin compete within the platinum chemotherapy class but have different formulation and handling profiles.

Factor	Carboplatin	Cisplatin
Conventional formulation	Aqueous injection	Aqueous injection
Relative chemical stability	Generally higher than cisplatin	More reactive and compatibility-sensitive
Dose-limiting toxicity profile	More myelosuppression	More nephrotoxicity and neurotoxicity concerns
Hydration burden	Generally lower	Often significant
Formulation complexity	Low to moderate	Moderate
Excipient differentiation	Ready-to-use and compatibility systems	Stability, hydration, and administration systems
Generic competition	Mature	Mature
Biosimilar relevance	None	None

The comparison supports a commercial strategy based on workflow and supply reliability rather than a novel excipient platform. Carboplatin already has a relatively manageable aqueous formulation. The product must therefore create value through administration efficiency, stability, safety, or availability.

What generic launch risks exist?

A new carboplatin product faces several launch risks:

1. Generic price compression can eliminate the premium for a modest formulation improvement.
2. Hospitals may prefer incumbent suppliers with established shortage performance.
3. A ready-to-use product may create inventory waste if dosing demand is variable.
4. A new container or transfer system may require extensive compatibility data.
5. Patent claims directed to a new presentation may be narrow and vulnerable to design-around.
6. FDA review may focus on equivalence, sterility, impurities, and container compatibility rather than clinical differentiation.
7. Manufacturing interruptions can erase the benefit of a technically superior formulation.

The strongest launch profile is a product that combines a defensible patent position with measurable pharmacy savings and a dependable sterile supply chain.

What is the revenue exposure of Paraplatin?

Standalone Paraplatin revenue is difficult to separate from the broader carboplatin market because generic products have replaced much of the branded commercial base. The relevant revenue exposure is concentrated in:

• carboplatin active pharmaceutical ingredient supply;
• sterile-fill manufacturing;
• hospital contracts;
• ready-to-use oncology bags;
• hazardous-drug transfer systems;
• specialty pharmacy and infusion-center distribution; and
• shortage-driven purchasing.

For an incumbent manufacturer, the core Paraplatin brand has limited strategic value unless it retains a differentiated presentation, supply advantage, or institutional contract position. For an excipient or delivery-system supplier, the opportunity is broader because the same platform may apply to other cytotoxic injections, including cisplatin, oxaliplatin, paclitaxel, and fluorouracil, subject to product-specific compatibility validation.

Key Takeaways

• Paraplatin is a simple sterile aqueous carboplatin injection with Water for Injection as the principal excipient.
• The original carboplatin patent estate is expired, and generic competition is established.
• Carboplatin has no biosimilar pathway because it is a small-molecule drug.
• Aluminum avoidance is a critical compatibility requirement and creates opportunities for validated packaging and administration systems.
• The strongest commercial opportunities are ready-to-use bags, closed-system transfer presentations, higher-concentration products, and workflow-reducing packaging.
• New patents are more likely to cover formulation performance, packaging, delivery devices, or manufacturing methods than carboplatin itself.
• Commercial success depends more on sterile manufacturing, shortage resilience, hospital contracting, and pharmacy labor savings than on a new excipient alone.
• A conventional reformulation with no workflow or stability advantage is unlikely to support a durable premium.

FAQs

Is carboplatin injection preservative-free?

Conventional carboplatin injection is generally supplied as a preservative-free sterile product. Water for Injection is the primary excipient in the standard formulation.

Can carboplatin be formulated with common buffers?

Buffer selection requires product-specific compatibility and stability studies. A buffer that changes pH or ionic composition can affect impurity formation, container compatibility, and shelf life.

Does carboplatin require refrigeration?

Storage requirements depend on the specific approved product and presentation. The applicable product label controls storage temperature, light protection, dilution conditions, and in-use dating.

Can a ready-to-use carboplatin bag receive five-year patent protection?

A ready-to-use bag could receive patent protection if it satisfies novelty and non-obviousness requirements, particularly through a defined formulation, container system, stability profile, or manufacturing process. Patent term and enforceability would depend on the claims and filing strategy.

Is a carboplatin shortage an excipient opportunity?

Shortages can create demand for alternative presentations, but the limiting factor is usually sterile manufacturing capacity rather than excipient availability. A differentiated excipient or packaging system has commercial value only if it supports reliable production and regulatory approval.

References

1. U.S. Food and Drug Administration. (2023). Paraplatin (carboplatin) injection prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,657,927: Carboplatin compounds and pharmaceutical compositions.
4. National Cancer Institute. (n.d.). Carboplatin.
5. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding, sterile preparations.